- Conditions
- Opiate Dependence
- Interventions
- Behavioral: Buprenorphine/naloxone maintenance (Mtn), Behavioral: Buprenorphine/naloxone detoxification (Dtx)
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 6,315
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Primary Immune Deficiency Disorder, Osteopetrosis, Cytopenia, Hemoglobinopathy in Children, Anemia, Aplastic
- Interventions
- BPX-501 T cells, Rimiducid
- Biological · Drug
- Lead sponsor
- Bellicum Pharmaceuticals
- Industry
- Eligibility
- 1 Month to 26 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2034
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Breast Cancer
- Interventions
- Docetaxel, Capecitabine
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-resistant Fallopian Cancer, Platinum-resistant Peritoneal Cancer
- Interventions
- CRS-207, Epacadostat, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Aduro Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Stanford, California • Gainesville, Florida + 6 more
- Conditions
- Raynaud's Disease, Peripheral Vascular Disease
- Interventions
- PF-00489791
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 23
- States / cities
- Redwood City, California • Farmington, Connecticut • Washington D.C., District of Columbia + 19 more
- Conditions
- Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- oxaliplatin
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more
- Conditions
- Myeloproliferative Disorder, Myeloproliferative Syndrome, Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia
- Interventions
- USDA Diet, Mediterranean Diet
- Other
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Obesity, Lifestyle, Healthy, Community Based Programs, Primary Care Referrals
- Interventions
- Referral to weight loss program
- Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- STEMI
- Interventions
- Non Intervention, Agressive Intervention Process Improvement Strategies
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- Not listed
- Enrollment
- 882 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Pterygium
- Interventions
- CBT-001 single dose, Vehicle, CBT-001 Multi-dose
- Drug
- Lead sponsor
- Cloudbreak Therapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Laguna Beach, California
- Conditions
- Obesity
- Interventions
- Health Smart for Weight Loss
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 21 Years to 100 Years · Female only
- Enrollment
- 683 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- rituximab
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Interventions
- cevimeline hydrochloride
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- autologous immunoglobulin idiotype-KLH conjugate vaccine
- Drug
- Lead sponsor
- Genitope Corporation
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Indianapolis, Indiana + 6 more
- Conditions
- Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Chronic Lymphocytic Leukemia, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Hepatosplenic T-Cell Lymphoma, Intraocular Lymphoma, Lymphomatous Involvement of Non-Cutaneous Extranodal Site, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Primary Cutaneous B-Cell Non-Hodgkin Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, T-Cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- Alisertib, Laboratory Biomarker Analysis, Pharmacological Study, Vorinostat
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 5
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 2 more
- Conditions
- Hypotension, Orthostatic
- Interventions
- midodrine hydrochloride (ProAmatine®)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 3
- States / cities
- St. Petersburg, Florida • Upland, Pennsylvania • San Antonio, Texas
- Conditions
- Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Recurrent Ovarian Cancer, Fallopian Tube Cancer
- Interventions
- Usual Care Educational Website, Prototype System
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Immune Thrombocytopenia
- Interventions
- INCA000585
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 9
- States / cities
- Glendale, Arizona • Los Angeles, California • Lone Tree, Colorado + 6 more
- Conditions
- Osteoarthritis
- Interventions
- Lumiracoxib
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 833 participants
- Timeline
- Started 2004
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Brooklyn Park, Minnesota • Albuquerque, New Mexico + 2 more
- Conditions
- Hyperlipidemia, Dyslipidemia
- Interventions
- NK-104-CR, Placebo, Livalo
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 45
- States / cities
- Beverly Hills, California • Chino, California • Lincoln, California + 42 more
- Conditions
- Primary Progressive Aphasia
- Interventions
- Communication Bridge™, Evidence-Based Impairment Focused
- Behavioral
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Primary Prevention, Healthy Aging, Quality of Life, Decision Support Techniques
- Interventions
- Individualized preventive care recommendations (decision tool)
- Behavioral
- Lead sponsor
- Glen Taksler
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 721 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
- Interventions
- thalidomide, doxorubicin hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Primary Insulin-like Growth Factor-1 Deficiency
- Interventions
- mecasermin [rDNA origin] injection
- Biological
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Basking Ridge, New Jersey